CVRx (CVRX) AI Stock Analysis

• Market Cap: $157.48M
• Dividend Yield: N/A
• Average Volume (3M): 228.91K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.37
• Revenue Growth: 25.62%
• EPS Growth: 11.86%
• Country: US
• Employees: 206
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Devices
• EPS (TTM): -0.53
• Shares Outstanding: 26,072,600
• 10 Day Avg. Volume: 173,988
• 30 Day Avg. Volume: 228,910
• PEG Ratio: 10.64
• Price to Book (P/B): 8.57
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -16.43
• Enterprise Value/Market Cap: 3.75
• Enterprise Value/Revenue: 3.02
• Enterprise Value/Gross Profit: 13.36
• Enterprise Value/Ebitda: -2.73
• 1Y Price Target: $12.60
• Price Target Upside: 95.05% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 53 Neutral
• Price Target: $6.50 ▲(0.62%Upside)

CVRx's overall score is primarily impacted by financial challenges, including significant net losses and negative cash flows. Technical indicators suggest a bearish trend, and valuation metrics are unattractive due to a negative P/E ratio. While the earnings call highlights strategic initiatives and moderate revenue growth, short-term execution risks persist.

Positive Factors

New Hires and Salesforce Development

Management is thrilled with the experience of new reps onboarding, the majority of whom have experience in therapy development and stakeholder relationships.

Product Differentiation

Barostim is seen as a differentiated solution in a large and under-penetrated market with little to no treatment options for the majority of patients.

Reimbursement Proposal

The next catalyst for CVRX will be the July reimbursement proposal for CMS, potentially creating a permanent outpatient category which could remove part of the multi-year overhang on the stock.

Negative Factors

Account Disruption

The planned salesforce reorganization led to greater than expected turnover and account disruption, resulting in lowered guidance.

Cash Flow Uncertainty

The trajectory to cash flow breakeven is uncertain due to potential rate changes and choppiness in sales growth trends.

Salesforce Turnover

Greater seasonality than expected and increased turnover that was over 90% company initiated impacted results.

CVRx Business Overview & Revenue Model

Company Description

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

How the Company Makes Money

CVRx generates revenue primarily through the sale of its Barostim System to hospitals and healthcare providers. The company may also engage in partnerships with healthcare institutions and organizations to facilitate the adoption and integration of its technology into clinical practice. Additionally, CVRx may receive revenue from service agreements related to the installation, training, and maintenance of its devices. The company's earnings are influenced by factors such as the adoption rate of its technology, market penetration, and reimbursement policies from insurance providers.

CVRx Financial Statement Overview

Summary

CVRx demonstrates robust revenue growth in the medical devices industry but faces challenges in profitability and cash flow management. The balance sheet indicates a stable financial structure with manageable debt, yet the company struggles with negative returns on equity. The firm needs to focus on improving operational efficiencies and cash flow management to enhance financial health.

Income Statement

CVRx shows a strong revenue growth with a 34.6% increase from 2023 to TTM (Trailing-Twelve-Months). However, the company is facing significant net losses with a negative net profit margin of -97.5% in TTM, indicating challenges in achieving profitability. The negative EBIT and EBITDA margins further highlight operational inefficiencies.

Balance Sheet

The company's equity ratio stands at 53.5% in TTM, indicating a moderate level of equity financing. However, the debt-to-equity ratio is 0.72, suggesting a manageable level of debt. The negative net income leads to a negative ROE, signaling challenges in generating shareholder returns.

Cash Flow

CVRx shows a negative free cash flow, albeit with a slight improvement in free cash flow growth from the previous period. The operating cash flow to net income ratio is negative, reflecting ongoing cash flow constraints. The company has a healthy cash position from financing activities, providing liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	52.87M	51.29M	39.30M	22.47M	13.04M	6.05M
Gross Profit	44.25M	42.96M	33.04M	17.47M	9.40M	4.61M
EBITDA	-51.87M	-54.89M	-38.73M	-40.74M	-40.60M	-11.48M
Net Income	-51.55M	-59.97M	-41.20M	-41.43M	-43.08M	-14.11M
Balance Sheet
Total Assets	129.59M	133.41M	115.23M	124.94M	152.55M	64.78M
Cash, Cash Equivalents and Short-Term Investments	102.67M	105.93M	90.57M	106.19M	142.07M	59.11M
Total Debt	50.13M	50.43M	30.61M	7.09M	0.00	19.28M
Total Liabilities	60.23M	62.36M	39.28M	15.76M	6.59M	358.01M
Stockholders Equity	69.36M	71.06M	75.95M	109.18M	145.96M	-293.24M
Cash Flow
Free Cash Flow	-41.57M	-40.51M	-39.61M	-43.36M	-28.91M	-16.41M
Operating Cash Flow	-41.02M	-39.14M	-39.02M	-42.68M	-27.73M	-16.10M
Investing Cash Flow	-558.00K	-1.36M	-591.00K	-685.00K	-1.18M	-311.00K
Financing Cash Flow	64.12M	55.87M	23.98M	7.49M	111.88M	49.78M

CVRx Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 6.46
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVRX, the sentiment is Neutral. The current price of 6.46 is above the 20-day moving average (MA) of 6.09, above the 50-day MA of 6.43, and below the 200-day MA of 10.91, indicating a neutral trend. The MACD of -0.18 indicates Negative momentum. The RSI at 53.85 is Neutral, neither overbought nor oversold. The STOCH value of 71.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CVRX.

CVRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BWAY	75 Outperform	$245.34M	59.10	7.41%	―	26.86%	―
MASS	56 Neutral	$232.38M	―	-44.97%	―	21.06%	-99.70%
CVRX	53 Neutral	$157.48M	―	-76.01%	―	25.62%	11.86%
MYO	53 Neutral	$77.71M	―	-35.68%	―	69.17%	39.01%
Sector *	51 Neutral	$7.55B	0.30	-61.90%	2.27%	17.11%	1.58%
TLSI	50 Neutral	$195.58M	―	271.41%	―	85.03%	53.73%
LNSR	48 Neutral	$152.26M	―	-304.05%	―	28.24%	-334.39%

CVRx Corporate Events

CVRx Confirms Directors and Accounting Firm at Meeting

On June 3, 2025, CVRx, Inc. held its annual meeting of stockholders where key decisions were made. The election of two Class I directors, Kevin Ballinger and Mitch Hill, was confirmed, and the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. These decisions are pivotal for CVRx’s governance and financial oversight, potentially impacting its strategic direction and stakeholder confidence.

The most recent analyst rating on (CVRX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on CVRx stock, see the CVRX Stock Forecast page.